BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
34.85
-0.97 (-2.71%)
May 8, 2025, 4:00 PM EDT - Market closed
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 11 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 57.09, with a low estimate of 45 and a high estimate of 95. The average target predicts an increase of 63.82% from the current stock price of 34.85.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Maintains $52 → $55 | Buy | Maintains | $52 → $55 | +57.82% | Apr 30, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $46 → $63 | Buy | Maintains | $46 → $63 | +80.77% | Apr 30, 2025 |
| UBS | UBS | Strong Buy Maintains $65 → $72 | Strong Buy | Maintains | $65 → $72 | +106.60% | Apr 30, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $53 | Strong Buy | Maintains | $49 → $53 | +52.08% | Apr 15, 2025 |
| Redburn Atlantic | Redburn Atlantic | Strong Buy Initiates $50 | Strong Buy | Initiates | $50 | +43.47% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
252.23M
from 221.90M
Increased by 13.67%
Revenue Next Year
549.91M
from 252.23M
Increased by 118.02%
EPS This Year
-3.83
from -2.88
EPS Next Year
-2.72
from -3.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 414.4M | 737.2M | 1.5B | ||
| Avg | 252.2M | 549.9M | 1.1B | ||
| Low | 138.2M | 336.2M | 752.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 86.8% | 192.3% | 167.1% | ||
| Avg | 13.7% | 118.0% | 104.2% | ||
| Low | -37.7% | 33.3% | 36.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.66 | -1.67 | 0.65 | ||
| Avg | -3.83 | -2.72 | -0.46 | ||
| Low | -4.53 | -3.75 | -2.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.